Zepbound

News

Lilly UK recruits ex-England cricketer as obesity champion

Lilly UK's obesity champion Ashley Giles, who won the Ashes with England in 2005, is urging people struggling with their weight to ask for help.

News

GLP-1s drive Lilly's Q1, but it's reticent on oral launch

Investors are itching for news on the rollout of Lilly's oral weight-loss drug Foundayo, but there's little information in its first-quarter update.

News

Novo hits back at rivals with cut-price Wegovy subscriptions

Trying to claw back market share in the weight-loss category, Novo Nordisk has launched a subscription-based service for Wegovy cash payers.

News

Lilly unveils employer scheme for weight-loss drug Zepbound

Eli Lilly has added another channel to its selling options for obesity therapy Zepbound in the US, launching a programme directed at employers.

News

Black background scattered with red 'SALE' tickets

Novo Nordisk to cut GLP-1 prices in tough US market

Novo Nordisk has turned to pricing as a means to shore up its position in the increasingly competitive market for GLP-1 agonist therapies in the US.

News

Cartoon graphic of a woman with glasses holding thought bubbles in the palm of either hand, one with a check and one with a cross

Head-to-head trial dents Novo Nordisk's obesity hopes

Novo Nordisk slumps as its two-drug combination for weight loss, CagriSema, performs less well than Eli Lilly's rival Zepbound in a comparative trial.

Lilly UK recruits ex-England cricketer as obesity champion

GLP-1s drive Lilly's Q1, but it's reticent on oral launch

Novo hits back at rivals with cut-price Wegovy subscriptions

Lilly unveils employer scheme for weight-loss drug Zepbound

Novo Nordisk to cut GLP-1 prices in tough US market

Head-to-head trial dents Novo Nordisk's obesity hopes

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Zepbound

Editor's Picks